RxDoctor Payments Data

Cynthia Dillon, MD

Family Medicine · Redding, CANPI 1619977527

Payments from drug & device makers

$507in general payments, 2019–2025

Across 16 payments — averaging $31.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zynex Medical, Inc.$192
  • Amgen$146
  • Lilly USA, LLC$64
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$25
  • Novo Nordisk$19
  • Sanofi Pasteur Inc.$18
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$507100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$507 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$6,262
Medicare patients
43
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$81,123
EliquisApixaban56$71,797
XareltoRivaroxaban13$20,808
Breo ElliptaFluticasone/Vilanterol21$17,731
JanuviaSitagliptin Phosphate16$14,953
Gabapentin84$3,326
Albuterol Sulfate HfaAlbuterol Sulfate44$2,565
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,542
Levothyroxine Sodium216$2,471
Celecoxib41$2,457
Atorvastatin Calcium165$2,240
Omeprazole149$2,206
Losartan Potassium185$1,999
ValacyclovirValacyclovir Hcl21$1,702
Pantoprazole Sodium66$1,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$81,12357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →